血管紧张素转换酶抑制剂对糖尿病大鼠血浆PAI-1和tPA活性的影响  

Effect of ACE inhibitor on plasma activity of PA inhibitor-1 and tPA in diabetic rats

作　　者：高璐[1] 于德民[1] 

机构地区：[1]天津医科大学代谢病医院,卫生部与天津市激素与发育重点实验室,300070

出　　处：《中国糖尿病杂志》2010年第4期296-297,302,共3页Chinese Journal of Diabetes

基　　金：天津医科大学科学基金(2006KY34)

摘　　要：目的探讨血管紧张素转换酶抑制剂(ACEI)对糖尿病(DM)大鼠血浆纤溶酶原激活物抑制剂1(PAI-1)和组织型纤溶酶原激活物(tPA)活性的影响及其机制。方法将链脲佐菌素诱导的DM大鼠分为正常对照组、培哚普利治疗组、培哚普利联合一氧化氮合酶(NOS)抑制剂治疗组。治疗4周后比较各组血浆PAI-1和tPA活性及PAI-1/tPA比值。结果与正常对照组相比,DM大鼠血浆PAI-1活性和PAI-1/tPA比值显著升高,tPA活性降低。培哚普利治疗使PAI-1活性下降,tPA活性增加。联合NOS抑制剂在一定程度上抵消了培哚普利的这种作用。结论 DM状态下存在纤溶异常,ACEI能够通过内源性的NO改善纤溶平衡。Objective To investigate the effect and related mechanisms of perindopril on plasma activity of PAI-1 and tPA in diabetic rats. Methods DM rats induced by streptozotocin were randomly allocated into three groups to be treated or not with perindopril alone or combination with nitric oxide synthase（NOS） inhibitor for 4 weeks. The plasma activity of PAI-1 and tPA were measured after treatment. Results Compared with control group, the plasma activity of PAI-1 and the ratio of PAI-1 to tPA in DM rats increased significantly, and the plasma activity of tPA decreased. Perindopril treatment decreased the activity of PAI-1 and the ratio of PAI-1 to tPA, and increased the activity of tPA（all P~ 0. 05）. This effect was counteracted by the combination of NOS inhibitor. Conclusions Fibrinolytic abnormalities exist in diabetic statement. ACEI can improve fibirnolytic balance through endogenous NO.

关 键 词：血管紧张素转换酶抑制剂 糖尿病 纤溶酶原激活物抑制剂 组织型纤溶酶原激活物 

分 类 号：R587.1[医药卫生—内分泌]